To quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).
Study Type
OBSERVATIONAL
Enrollment
68,563
CorEvitas HQ
Waltham, Massachusetts, United States
Change in Visual Acuity (VA) in Participant's Study Eye
Change in visual acuity (VA) in participant's study eye is reported. Study eye is defined as the first eye with the disease, and fellow eye, the participant's second eye. Change in VA was determined by calculating the difference between mean visual acuity (VA) readings at index diagnosis, and mean at another timepoint, assessed yearly for participants with valid VA readings at both timepoints.
Time frame: From index date of GA diagnosis up to 5 years
Number of Participants Who Developed or Progressed to Age-related Macular Degeneration (wAMD) in the Study Eye
Number of participants who developed or progressed to age-related macular degeneration (wAMD) in the study eye is reported. The criteria used to determine progression through development to wAMD was identifying when ICD (International Classification of Diseases) codes for wAMD were present in the study eye.
Time frame: From index date of GA diagnosis up to 5 years.
Number of Participants Who Developed or Progressed to Geographic Atrophy (GA) in the Fellow Eye
Number of participants who developed or progressed to geographic atrophy (GA) in the fellow eye is reported. For patients diagnosed with GA at baseline, the development of GA in the fellow eye was closely monitored over time, with progress tracked for each year.
Time frame: From index date of GA diagnosis up to 5 years.
Change in Lesion Location for Participants With wAMD in Study Eye
Change in lesion location from extrafoveal to subfoveal in participants who developed wAMD in study eye is reported. Lesion location was assessed at index diagnosis and at each year, then stratified by whether a patient developed wAMD in the 5 years post diagnosis. Changes in lesion were calculated as the difference in the number of participants with extrafoveal location at index diagnosis of the study eye, compared to the number of participants with extrafoveal lesion in the study eye at each year.
Time frame: From index date of GA diagnosis up to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in Lesion Location for Participants With GA in Fellow Eye
Change in lesion location from extrafoveal to subfoveal in participants who developed GA in fellow eye is reported. Lesion location was assessed at index diagnosis and at each year, then stratified by whether a patient developed GA in the 5 years post diagnosis. Changes in lesion were calculated as the difference in the number of participants with extrafoveal location at index diagnosis of the study eye, compared to the number of participants with extrafoveal lesion in the study eye at each year.
Time frame: From index date of GA diagnosis up to 5 years
Occurrence of GA Over Study Period
Incidence and prevalence of GA over time is reported. This endpoint analyzed the yearly counts of newly diagnosed or prevalent cases to help in understanding the progression of the overall disease.
Time frame: Number of yearly counts of GA from 2018 to 2013, by quarterly average.
Retinal Disease-related Outcomes: Number of Visits Per Quarter in a Year
The retinal disease-related healthcare resource utilization (HCRU) outcome, number of visits by participants per quarter in a year is reported.
Time frame: Mean number of quarterly visits from 2019 up to 2023.
Retinal Disease-related Outcomes: Number of Anti-VEGF Injections Per Quarter
The retinal disease-related healthcare resource utilization (HCRU) outcome, number of anti-vascular endothelial growth factor (anti-VEGF) injections per quarter in a year is reported.
Time frame: Mean number of quarterly anti-VEGF injections from 2019 up to 2023.
Retinal Disease-related Outcomes: Number of Participants With Ocular Comorbidities by Year of Follow up
The retinal disease-related HCRU outcome, number of ocular comorbidities by year of follow up is reported.
Time frame: Total number of participants with ocular comorbidities were documented from index date up to 5 years.
HCRU Outcome: Number of Participants With the Medical Procedure of Corneal Transplant
The number of participants with corneal transplant during the observational period is reported.
Time frame: Total number of participants with corneal transplants were documented from index date up to 5 years.
HCRU Outcome: Number of Participants With the Medical Procedure of Incisional Glaucoma Surgery
Number of participants with incisional glaucoma surgery during the observational period is reported.
Time frame: Total number of participants with incisional glaucoma surgery were documented from index date up to 5 years.
HCRU Outcome: Number of Participants With the Medical Procedure of Vitrectomy
Number of participants with vitrectomy during the observational period is reported.
Time frame: Total number of participants with vitrectomy were documented from index date up to 5 years.